Clinical Trial Update: RTA 402 in Patients With Advanced Solid Tumors or Lymphoid Malignancies [Phase 1]

View source ↗

Summary

Phase 1 trial update of RTA 402 (bardoxolone methyl) in patients with advanced solid tumors or lymphoid malignancies; the study has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Lymphoid Malignancies
• Solid Tumors

Drugs mentioned

• RTA 402 (bardoxolone methyl)

Snippet

Sponsor: Biogen | Conditions: Advanced Solid Tumors, Lymphoid Malignancies | Phase 1 | Status: COMPLETED